Refractory B Acute Lymphoblastic Leukemia
Showing 1 - 15 of 15
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial
Not yet recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +5 more
- Interferon Beta-1A
- +10 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2023
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial in
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Biospecimen Collection
- +11 more
-
Birmingham, Alabama
- +152 more
Jan 30, 2023
Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia Trial
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- +7 more
- Anti-CD123 ADC IMGN632
- +7 more
- (no location specified)
Dec 28, 2022
Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,
Recruiting
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- +4 more
- ADCT-602
-
Monrovia, California
- +1 more
Dec 7, 2022
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in
Recruiting
- Recurrent Acute Leukemia
- +16 more
- Acetaminophen
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Cyclophosphamide
- +9 more
-
Houston, TexasM D Anderson Cancer Center
Nov 2, 2022
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in
Terminated
- Philadelphia Chromosome Negative
- +2 more
- Blinatumomab
- +11 more
-
Houston, TexasM D Anderson Cancer Center
Nov 3, 2022
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Blinatumomab
- +2 more
-
New Haven, Connecticut
- +6 more
Jul 9, 2022
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic
Terminated
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Cyclophosphamide
- +12 more
-
Houston, TexasM D Anderson Cancer Center
Apr 28, 2022
B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Apr 4, 2022
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 13, 2022
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic
Terminated
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
- +16 more
- Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 28, 2021
Dual-target CAR-T Cells, B ALL, Relapse Trial in Shenzhen (Dual target CAR-T cell therapy)
Unknown status
- Dual-target CAR-T Cells
- +3 more
- Dual target CAR-T cell therapy
-
Shenzhen, Guangdong, ChinaShenzhen University General hospital
Jan 23, 2021
Refractory B Acute Lymphoblastic Leukemia, Relapse B Acute Lymphoblastic Leukemia Trial in Xi'an (Dual Specificity CD19 and CD22
Withdrawn
- Refractory B Acute Lymphoblastic Leukemia
- Relapse B Acute Lymphoblastic Leukemia
- Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
-
Xi'an, Shaanxi, ChinaSecond Affiliated Hospital of Xi'an Jiaotong University
Nov 3, 2020